Prestige Consumer Healthcare (NYSE:PBH) Issues FY25 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) updated its FY25 earnings guidance on Thursday. The company provided EPS guidance of $4.40-4.46 for the period, compared to the consensus EPS estimate of $4.40. The company issued revenue guidance of $1.13-1.14 billion, compared to the consensus revenue estimate of $1.13 billion. Prestige Consumer Healthcare also updated its FY 2025 guidance to 4.400-4.460 EPS.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. StockNews.com downgraded Prestige Consumer Healthcare from a strong-buy rating to a buy rating in a research report on Tuesday, May 21st. DA Davidson reiterated a buy rating and set a $93.00 price objective on shares of Prestige Consumer Healthcare in a research report on Friday. Finally, Canaccord Genuity Group reiterated a buy rating and set a $80.00 price objective on shares of Prestige Consumer Healthcare in a research report on Tuesday, May 21st. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of Moderate Buy and an average price target of $98.25.

Prestige Consumer Healthcare Trading Down 0.9 %

NYSE:PBH traded down $0.59 on Friday, reaching $66.25. The company’s stock had a trading volume of 274,252 shares, compared to its average volume of 250,556. Prestige Consumer Healthcare has a 12-month low of $56.34 and a 12-month high of $75.31. The company has a quick ratio of 2.02, a current ratio of 3.20 and a debt-to-equity ratio of 0.68. The firm has a market cap of $3.29 billion, a price-to-earnings ratio of 15.89, a price-to-earnings-growth ratio of 2.00 and a beta of 0.49. The stock has a 50 day moving average price of $68.20 and a 200 day moving average price of $68.51.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 8th. The company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.86 by $0.04. Prestige Consumer Healthcare had a return on equity of 13.48% and a net margin of 18.60%. The company had revenue of $267.10 million for the quarter, compared to the consensus estimate of $260.54 million. During the same quarter in the previous year, the business earned $1.06 earnings per share. The company’s revenue for the quarter was down 4.4% on a year-over-year basis. On average, equities analysts anticipate that Prestige Consumer Healthcare will post 4.42 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.